BACKGROUND: Despite evidence of effective combination drug therapy for secondary prevention of coronary heart disease (CHD), older adults with this condition remain undertreated. OBJECTIVE: To describe time trends (1992-2003) in the adoption of combination cardiac drug therapies (beta-blockers [beta-adrenoceptor antagonists], ACE inhibitors or angiotensin II type 1 receptor antagonists [angiotensin receptor blockers; ARBs], and lipid-lowering agents) among older adults in the US with CHD and to identify factors associated with not using combination therapy. METHODS: The study took the form of a cross-sectional time-series. The study population consisted of a nationally representative sample of adults aged >or=65 years with CHD (unweighted n = 6331; weighted n = 20.1 million) included in the 1992-2003 Medicare Current Beneficiary Survey. The outcome measure was low-intensity cardiac pharmacotherapy (no drug or single drug therapy with beta-blockers, ACE inhibitors/ARBs or lipid-lowering agents) compared with combination therapy (>or=2 cardiac drugs) for secondary CHD prevention. RESULTS: The use of combination drug therapy in older adults with CHD increased 9-fold during the study period (from 6% in 1992 to 54% in 2003). Adjusted analyses demonstrate that suboptimal drug therapy was independently associated with advanced age (relative risk [RR] 1.18; 95% CI 1.14, 1.23) for patients aged >or=85 years versus patients aged 65-74 years, and with being non-Hispanic Black (RR 1.05; 95% CI 1.01, 1.10) or Hispanic (RR 1.13; 95% CI 1.06, 1.21) versus being non-Hispanic White. CONCLUSIONS: Combination drug therapy use for secondary CHD prevention increased in older US adults over the last decade, but improvements were not uniform. The oldest-old, non-Hispanic Blacks and Hispanics experienced slower adoption of optimal medical therapy to improve their long-term prognosis for CHD.
BACKGROUND: Despite evidence of effective combination drug therapy for secondary prevention of coronary heart disease (CHD), older adults with this condition remain undertreated. OBJECTIVE: To describe time trends (1992-2003) in the adoption of combination cardiac drug therapies (beta-blockers [beta-adrenoceptor antagonists], ACE inhibitors or angiotensin II type 1 receptor antagonists [angiotensin receptor blockers; ARBs], and lipid-lowering agents) among older adults in the US with CHD and to identify factors associated with not using combination therapy. METHODS: The study took the form of a cross-sectional time-series. The study population consisted of a nationally representative sample of adults aged >or=65 years with CHD (unweighted n = 6331; weighted n = 20.1 million) included in the 1992-2003 Medicare Current Beneficiary Survey. The outcome measure was low-intensity cardiac pharmacotherapy (no drug or single drug therapy with beta-blockers, ACE inhibitors/ARBs or lipid-lowering agents) compared with combination therapy (>or=2 cardiac drugs) for secondary CHD prevention. RESULTS: The use of combination drug therapy in older adults with CHD increased 9-fold during the study period (from 6% in 1992 to 54% in 2003). Adjusted analyses demonstrate that suboptimal drug therapy was independently associated with advanced age (relative risk [RR] 1.18; 95% CI 1.14, 1.23) for patients aged >or=85 years versus patients aged 65-74 years, and with being non-Hispanic Black (RR 1.05; 95% CI 1.01, 1.10) or Hispanic (RR 1.13; 95% CI 1.06, 1.21) versus being non-Hispanic White. CONCLUSIONS: Combination drug therapy use for secondary CHD prevention increased in older US adults over the last decade, but improvements were not uniform. The oldest-old, non-Hispanic Blacks and Hispanics experienced slower adoption of optimal medical therapy to improve their long-term prognosis for CHD.
Authors: S C Smith; S N Blair; R O Bonow; L M Brass; M D Cerqueira; K Dracup; V Fuster; A Gotto; S M Grundy; N H Miller; A Jacobs; D Jones; R M Krauss; L Mosca; I Ockene; R C Pasternak; T Pearson; M A Pfeffer; R D Starke; K A Taubert Journal: Circulation Date: 2001-09-25 Impact factor: 29.690
Authors: David A Alter; Douglas G Manuel; Nadia Gunraj; Geoff Anderson; C David Naylor; Andreas Laupacis Journal: Am J Med Date: 2004-04-15 Impact factor: 4.965
Authors: Randall S Stafford; Stephen M Davidson; Harriet Davidson; Heidi Miracle-McMahill; Sybil L Crawford; David Blumenthal Journal: Health Serv Res Date: 2003-04 Impact factor: 3.402
Authors: Chien-Wen Tseng; Edward F Tierney; Robert B Gerzoff; R Adams Dudley; Beth Waitzfelder; Ronald T Ackermann; Andrew J Karter; John Piette; Jesse C Crosson; Quyen Ngo-Metzger; Richard Chung; Carol M Mangione Journal: Diabetes Care Date: 2007-11-13 Impact factor: 19.112
Authors: Arleen F Brown; Amy G Gross; Peter R Gutierrez; Luohua Jiang; Martin F Shapiro; Carol M Mangione Journal: J Am Geriatr Soc Date: 2003-05 Impact factor: 5.562
Authors: Jennifer Tjia; Jeroan Allison; Jane S Saczynski; Mayra Tisminetzky; Jane L Givens; Kate Lapane; Darleen Lessard; Robert J Goldberg Journal: Am J Med Date: 2013-07-05 Impact factor: 4.965
Authors: Sarwat I Chaudhry; Rabeea F Khan; Jersey Chen; Kumar Dharmarajan; John A Dodson; Frederick A Masoudi; Yun Wang; Harlan M Krumholz Journal: J Am Heart Assoc Date: 2014-09-23 Impact factor: 5.501